We are open to partnering, contact our team at
Combining Artificial Intelligence (AI) and unique human challenge trial data to develop novel solutions
Influenza AI Programme
In March 2022 Poolbeg signed a deal with CytoReason, a leading AI company, to analyse Poolbeg’s unique influenza disease progression data.
This partnership harnessed the insights of our unique repository of influenza human challenge trial data together with CytoReason’s broad repositories of curated disease data and industry leading and validated AI technology to enable a deep understanding of the mechanism of influenza infection, progression and recovery.
The programme successfully identified multiple novel drug targets for this disease in June 2023. In October 2023, our Scientific Advisory Board (SAB) endorsed the prioritisation of a select number of targets. We are actively discussing the exciting outputs from our AI-led programmes with prospective partners.
Global Influenza in Numbers
1 BILLION
Estimated Global Cases
3-5 MILLION
Severe Cases
290k-650k
Respiratory Deaths Annually
World Health Organization, October 2023.
Respiratory Syncytial Virus (RSV) AI Programme
In February 2022 Poolbeg signed an agreement with OneThree Biotech, a biology-driven AI company, to identify new treatments for respiratory syncytial virus (RSV).
Poolbeg’s scientific team worked closely with OneThree to build a tailored AI approach that leverages Poolbeg’s unique RSV human challenge trial data in order to identify disease-relevant biological pathways and potential drug targets. Drug targets were successfully identified in November 2022 and based on those newly discovered drug targets; the collaboration identified a number of promising drug candidates. In December 2023, Poolbeg received positive outputs from lab-based analysis of these drug candidates and strategically prioritised a number of candidates with existing Phase I clinical data and which could potentially be repositioned as novel treatments for RSV infection. Candidates with solid safety and pharmacodynamic data in humans are well positioned to rapidly enter a clinical trial to generate early human efficacy data for RSV.
This significant breakthrough has demonstrated the power of AI in accelerating drug discovery and has re-enforced our confidence in the value of this proprietary data and our ability to work with partners to advance the science to bring new therapeutics to these areas of high unmet medical needs. We are actively discussing the exciting outputs from our AI-led programmes with prospective partners.
RSV In Numbers
~33 MILLION
People affected annually
~4 MILLION
Hospitalisations
~101,000
RSV attributable deaths in children under five years
Li Y et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19. PMID: 35598608; PMCID: PMC7613574.
AI Programmes Underpinned by Unique Human Challenge Trial Data
Proprietary data set enables training of cutting-edge AI algorithms leading to higher quality outputs
Poolbeg Pharma has access to a unique private repository of clinical samples and associated data from human challenge trials. Data from human challenge trials are unique in that they track a healthy subject through disease to recovery in carefully controlled and monitored isolation units, collecting samples throughout the course of disease, and vitally collecting matched baseline and follow-up samples before and after infection. This data is unique in the depth of longitudinal virology, health, biomarker and symptom data collected during the course of disease.
Our lead candidate, POLB 001, was identified using such disease progression data, however by utilising AI, Poolbeg has identified more targets, quicker and more cost efficiently than previously possible without this technology.
